Sleepio is a revolutionary digital treatment for insomnia
Helping people overcome their insomnia for good with care that’s available anytime, anywhere.
In a clinical trial, 76% of patients experienced clinically significant improvement in insomnia
54%
reduction in time to fall asleep.1
62%
less time awake at night.1
45%
better functioning the next day.1
For the past decade, we’ve been putting Sleepio to the test in gold-standard clinical trials.
Sleepio use was shown to lower health care costs by $1,677 per employee*
A health economic evaluation with IBM Watson Health and a Fortune 500 employer demonstrated that Sleepio generated a significant per-employee health care cost reduction.2
Sleepio delivers meaningful, lasting results
Sleepio addresses unique needs with a customized program featuring sessions with step-by-step guidance through evidence-based techniques. In about 20 minutes per week, individuals can quiet their racing minds, reshape behaviors, and get better sleep.
Customized therapeutic content
Sleepio adjusts therapeutic content to each individual’s needs and offers additional tools and insights when needed.
Help at any time, day or night
When it’s needed the most, Sleepio is instantly accessible and ready to check in, practice, or try a new technique.
Progress tracking
Sleepio provides customized goal setting, a detailed sleep diary, and helps track progress over time.
Poor sleep affects up to 33% of workers
About one in three US adults suffer from poor sleep and as a result are at increased risk of reduced workplace performance and functioning, including reduced focus, increased risk of injury, and poorer mental health.3-6 Though accessible, commonly prescribed sleep medications can cause side effects like drowsiness and memory loss.7,8
Learn why more and more organizations are focusing on employee sleep and mental health
Improving productivity in automotive workers with quality sleep
A case study examining Sleepio adoption and outcomes in employees of an integrated automotive services company.
Five eye-opening ways sleep impacts your employees
Poor sleep is associated with decreased physical and mental health, but it also raises the risk of on-the-job accidents and…
Do you struggle to drive employee engagement with mental health care?
Everyone sleeps! Which is why employees are often more comfortable receiving support for poor sleep than mental health.
During the COVID-19 public health emergency, Sleepio is temporarily being made available as a treatment for insomnia disorder without a prescription. Sleepio has not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.
1. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
2. Miller, C. B., Carl, J. R., Henry, A. L., Baker, L. (2020). A health economic evaluation of Sleepio at a Fortune 500 company. Retrieved from: https://go.bighealth.com/report/health-economic-evaluation. *This is a total estimate that is based on statistically significant and non-significant reductions in costs across categories; thus the exact figure would require confirmation in further research with a larger sample size.
3. CDC – Data and Statistics – Sleep and Sleep Disorders. (2017). CDC. https://www.cdc.gov/sleep/data_statistics.html
4. Varkevisser, M., & Kerkhof, G. A. (2005). Chronic insomnia and performance in a 24‐h constant routine study. Journal of Sleep Research, 14(1), 49-59.
5. Shahly, V., Berglund, P. A., Coulouvrat, C., Fitzgerald, T., Hajak, G., Roth, T., … & Kessler, R. C. (2012). The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Archives of general psychiatry, 69(10), 1054-1063.
6. Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., … & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep medicine reviews, 43, 96-105.
7. Sanofi-Aventis U.S. LLC. (2008). Ambien prescribing information: NDA 19908 S027 FDA approved labeling 4.23.08. Retrieved Jul 25, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf.
8. Sunovion Pharmaceuticals Inc. (2014). Lunesta prescribing information. Retrieved Jul 25, 2023, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf.
DOC-3043 Effective 07/2023
